Orlando, FL - ASCO 2009 Annual Meeting: Gordon J Rustin, MD discusses Abstract 1 - A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). during the Plenary at the American Society for Clinical Oncology Annual Meeting, Sunday May 31, 2009. Photo by © ASCO/Todd Buchanan 2009 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.
Orlando, FL - ASCO 2009 Annual Meeting: Gordon J Rustin, MD discusses Abstract 1 - A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). during the Plenary at the American Society for Clinical Oncology Annual Meeting, Sunday May 31, 2009. Photo by © ASCO/Todd Buchanan 2009 Technical Questions: todd@toddbuchanan.com; Phone: 612-226-5154.